NCT05282459 2026-04-17
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Stanford University
Phase 1/2 Completed
Clinical Trials
4 trialsNCT06235801 2025-11-19
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT03080922 2017-04-04
High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 1/2 Unknown
NCT01864902 2016-01-28
CART33
Chinese PLA General Hospital
Phase 1/2 Unknown